Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allogeneic human adipose-derived mesenchymal stem cell therapy - AbelZeta Pharma

Next Previous
Drug Profile

Allogeneic human adipose-derived mesenchymal stem cell therapy - AbelZeta Pharma

Alternative Names: Allogenic Adipose tissue-derived mesenchymal progentior cells; Allogenic haMPC therapy - AbelZeta Pharma; AlloJoin; Mesenchymal progenitor cells

Latest Information Update: 23 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellular Biomedicine Group
  • Developer AbelZeta Pharma; Renji Hospital
  • Class Antirheumatics; Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis
  • Suspended Gram-negative infections

Most Recent Events

  • 14 Jan 2026 ElpasBio and Fosun Kairos announce commercialisation collaboration for AlloJoin® stem cell therapy in China, Hongkong and Macau
  • 26 Aug 2024 AbelZeta Pharma plans a phase III trial for Osteoarthritis (In adults, In the elderly) (Intra-articular, Injection) in October 2024 (NCT06570291)
  • 22 Jul 2024 Suspended - Phase-I/II for Gram-negative infections in China (Inhalation) (NCT04544215)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top